Oral Azacitidine Combination Met Phase 3 Trial Goals
Adults with specific blood disorders may soon have an oral treatment option if federal regulators approve this drug combination.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Do you believe oral treatment options are generally preferable to injectable therapies for chronic health conditions?
An investigational oral drug combination, known as ASTX030, met its primary pharmacokinetic goal in a phase 3 clinical trial for adults with myelodysplastic syndromes or chronic myelomonocytic leukemia. Taiho Oncology now plans to submit an application to the FDA to seek approval for this oral regimen.
Why it matters
Currently, standard treatments often require parenteral administration, so this oral alternative could significantly improve convenience and access for patients managing these chronic blood conditions. This development marks a shift toward potentially offering a more patient-friendly delivery method for established DNA methyltransferase inhibitors.
In a phase 3 randomized, open-label crossover study of 88 adults, the oral combination of azacitidine and cedazuridine achieved the primary pharmacokinetic end point when compared to subcutaneous administration. These findings are considered preliminary as the full study enrollment of 316 is ongoing.
The players
Taiho Oncology
A pharmaceutical company that develops innovative cancer treatments and is the sponsor of the ASTX030 clinical development program.
The details
The experimental therapy ASTX030 pairs azacitidine, a DNA methyltransferase inhibitor, with cedazuridine, a cytidine deaminase inhibitor. The cedazuridine component works by inhibiting the breakdown of azacitidine, allowing it to remain active within the body when taken orally. In the trial, participants were required to swallow the medication within 10 minutes and maintain a 4-hour fast to ensure proper absorption.
Timeline
September 30, 2026: Topline results from the phase 3 clinical trial were released.
October 1, 2026: The trial findings were officially published.
Health Landscape
The development of ASTX030 reflects a broader push in oncology to transition injectable cancer therapies into oral regimens. This effort follows the path established by the AZTOUND clinical trial program, which seeks to maintain therapeutic drug levels while reducing the burden of clinical administration.
If you are currently undergoing treatment for myelodysplastic syndromes or chronic myelomonocytic leukemia, discuss whether oral regimen developments might eventually align with your care plan. It is important to wait for formal FDA approval and official provider guidance before considering any changes to your current treatment protocol.
The takeaway
This oral combination may eventually offer a more manageable way to deliver DNA methyltransferase inhibitors. Patients interested in future treatment options should keep track of the upcoming FDA filing status and discuss the implications for their own care with their hematologist or oncologist.
Further reading
For more information on the current landscape of research for blood-related malignancies, visit our Cancer section.
More information
You can review the study design and patient eligibility criteria in the AZTOUND clinical trial details.
Live Poll
Do you believe oral treatment options are generally preferable to injectable therapies for chronic health conditions?
